ArticleClinical rheumatology2026
Subclinical inflammation in pediatric familial Mediterranean fever: predictors and follow-up results of a retrospective single-center cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesFamilial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease in childhood. Subclinical inflammation is defined as persistently elevated acute phase reactants despite the absence of clinical attacks. The aim of this study was to determine the frequency of subclinical inflammation and its clinical predictors in pediatric FMF patients, and to assess treatment responses following therapeutic adjustments.
methodsMedical records of FMF patients followed between January 2011 and February 2024 were retrospectively reviewed. Patients were grouped based on the presence of subclinical inflammation, and clinical features, genetics, and treatment responses were compared to identify risk factors for subclinical inflammation.
resultsA total of 572 pediatric FMF patients were included, of whom 89 (15.6%) exhibited subclinical inflammation. Patients with subclinical inflammation had significantly earlier disease onset, longer disease duration, numerically more frequent comorbid conditions, and more biallelic exon 10 mutations (p < 0.05). In addition, arthritis and higher disease severity scores were detected as independent predictors of subclinical inflammation. Regarding treatment, 45% of patients with subclinical inflammation achieved resolution after colchicine dose adjustments. However, 55% required biologic therapies. Among biologic-treated patients, 87.7% showed normalization of inflammatory markers, whereas 12.3% continued to exhibit persistent inflammation; all of these patients had comorbid conditions.
conclusionSubclinical inflammation is common in pediatric FMF patients. Our findings suggest that earlier disease onset, biallelic exon 10 mutations, arthritis, and higher disease severity scores are associated with persistent inflammation. Colchicine dose optimization effectively controls inflammation in nearly half of these patients, while biologic therapies, particularly IL-1 inhibitors, are effective for the remaining cases. KEY POINTS: • Subclinical inflammation is common in pediatric FMF patients. • Early disease onset, biallelic exon 10 mutations, arthritis, and higher disease severity scores are associated with subclinical inflammation. • Colchicine dose adjustments are effective for nearly half of patients, while biologic therapies, particularly IL-1 inhibitors, are needed for the rest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.